Luis Fonseca-Ornelas

Luis Fonseca-Ornelas

Auto-generated profile, based on publicly available information

Luis Fonseca-Ornelas

Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2016 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
LTLars Tatenhorst
Lars Tatenhorst
KEKatrin Eckermann
Katrin Eckermann
VDVivian Dambeck
Vivian Dambeck
LFLuis Fonseca-Ornelas
Luis Fonseca-Ornelas
HWHagen Walle
Hagen Walle
Paul LingorPaul Lingor
Paul Lingor
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, yet disease-modifying treatments do not currently exist. Rho-associated protein kinase (ROCK) was recently described as a novel neuroprotective target in PD. Since alpha-synuclein (α-Syn) aggregation is a major hallmark in the pathogenesis of PD, we aimed to evaluate the anti-aggregative potential of pharmacological ROCK inhibition using the isoquinoline derivative Fasudil, a small molecule inhibitor already approved for clinical use in humans. Fasudil treatment significantly reduced α-Syn aggregation in vitro in a H4 cell culture model as well as in a cell-free assay. Nuclear magnetic resonance spectroscopy analysis revealed a direct binding of Fasudil to tyrosine residues Y133 and Y136 in the C-terminal region of α-Syn. Importantly, this binding was shown to be biologically relevant using site-directed mutagenesis of these residues in the cell culture model. Furthermore, we evaluated the impact of long-term Fasudil treatment on α-Syn pathology in vivo in a transgenic mouse model overexpressing human α-Syn bearing the A53T mutation (α-SynA53T mice). Fasudil treatment improved motor and cognitive functions in α-SynA53T mice as determined by CatwalkTM gait analysis and novel object recognition (NOR), without apparent side effects. Finally, immunohistochemical analysis revealed a significant reduction of α-Syn pathology in the midbrain of α-SynA53T mice after Fasudil treatment. Our results demonstrate that Fasudil, next to its effects mediated by ROCK-inhibition, directly interacts with α-Syn and attenuates α-Syn pathology. This underscores the translational potential of Fasudil as a disease-modifying drug for the treatment of PD and other synucleinopathies.

3 March 2017 in PLOS Biology
Verified
Journal Article
Open access
PDF file
RORita Machado de Oliveria
Rita Machado de Oliveria
Hugo Vicente MirandaHugo Vicente Miranda
Hugo Vicente Miranda
LFLaetitia Francelle
Laetitia Francelle
RPRaquel Pinho
Raquel Pinho
ÉSÉva M. Szegö
Éva M. Szegö
Tiago OuteiroTiago Outeiro
Tiago Outeiro
Sirtuin genes have been associated with aging and are known to affect multiple cellular pathways. Sirtuin 2 was previously shown to modulate proteotoxicity associated with age-associated neurodegenerative disorders such as Alzheimer and Parkinson disease (PD). However, the precise molecular mechanisms involved remain unclear. Here, we provide mechanistic insight into the interplay between sirtuin 2 and α-synuclein, the major component of the pathognomonic protein inclusions in PD and other synucleinopathies. We found that α-synuclein is acetylated on lysines 6 and 10 and that these residues are deacetylated by sirtuin 2. Genetic manipulation of sirtuin 2 levels in vitro and in vivo modulates the levels of α-synuclein acetylation, its aggregation, and autophagy. Strikingly, mutants blocking acetylation exacerbate α-synuclein toxicity in vivo, in the substantia nigra of rats. Our study identifies α-synuclein acetylation as a key regulatory mechanism governing α-synuclein aggregation and toxicity, demonstrating the potential therapeutic value of sirtuin 2 inhibition in synucleinopathies. Parkinson disease is an age-associated neurodegenerative disorder characterized by the loss of dopamine-producing neurons from a region in the brain known as the substantia nigra and by the accumulation of the protein alpha-synuclein in intracellular clumps called inclusions. Whether these inclusions are the cause or a consequence of the pathological processes is still unclear. Sirtuin proteins are considered master regulators of the ageing process and have previously been associated with neurodegeneration. In this study, we investigated the interplay between sirtuin 2 and alpha-synuclein in order to dissect the molecular mechanisms associated with protection against alpha-synuclein toxicity. We found that sirtuin 2 interacted with and removed acetyl groups from alpha-synuclein. By decreasing the levels of sirtuin 2, or by expressing mutant versions of alpha-synuclein that modulate its acetylation status, we found that acetylation reduces the aggregation of alpha-synuclein and its cytotoxicity in vitro. Next, we evaluated whether genetic inhibition of sirtuin 2 could prevent the deleterious effects of alpha-synuclein in vivo and found that, in two different models of Parkinson disease, deletion of sirtuin 2 was neuroprotective. Our data therefore suggest that strategies aimed at decreasing sirtuin 2 activity might prove valuable therapeutic avenues for intervention in Parkinson disease and other synucleinopathies.

16 January 2023 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
NRNagendran Ramalingam
Nagendran Ramalingam
SJShan-Xue Jin
Shan-Xue Jin
TMTim E. Moors
Tim E. Moors
LFLuis Fonseca-Ornelas
Luis Fonseca-Ornelas
KSKazuma Shimanaka
Kazuma Shimanaka
UDUlf Dettmer
Ulf Dettmer
In Parkinson’s disease and other synucleinopathies, the elevation of α-synuclein phosphorylated at Serine129 (pS129) is a widely cited marker of pathology. However, the physiological role for pS129 has remained undefined. Here we use multiple approaches to show for the first time that pS129 functions as a physiological regulator of neuronal activity. Neuronal activity triggers a sustained increase of pS129 in cultured neurons (200% within 4 h). In accord, brain pS129 is elevated in environmentally enriched mice exhibiting enhanced long-term potentiation. Activity-dependent α-synuclein phosphorylation is S129-specific, reversible, confers no cytotoxicity, and accumulates at synapsin-containing presynaptic boutons. Mechanistically, our findings are consistent with a model in which neuronal stimulation enhances Plk2 kinase activity via a calcium/calcineurin pathway to counteract PP2A phosphatase activity for efficient phosphorylation of membrane-bound α-synuclein. Patch clamping of rat SNCA−/− neurons expressing exogenous wild-type or phospho-incompetent (S129A) α-synuclein suggests that pS129 fine-tunes the balance between excitatory and inhibitory neuronal currents. Consistently, our novel S129A knock-in (S129AKI) mice exhibit impaired hippocampal plasticity. The discovery of a key physiological function for pS129 has implications for understanding the role of α-synuclein in neurotransmission and adds nuance to the interpretation of pS129 as a synucleinopathy biomarker.

19 December 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
LFLuis Fonseca-Ornelas
Luis Fonseca-Ornelas
SESybille E. Eisbach
Sybille E. Eisbach
MPMaria Paulat
Maria Paulat
KGKarin Giller
Karin Giller
CFClaudio O. Fernandez
Claudio O. Fernandez
MZMarkus Zweckstetter
Markus Zweckstetter
α-synuclein is an abundant presynaptic protein that is important for regulation of synaptic vesicle trafficking, and whose misfolding plays a key role in Parkinson’s disease. While α-synuclein is disordered in solution, it folds into a helical conformation when bound to synaptic vesicles. Stabilization of helical, folded α-synuclein might therefore interfere with α-synuclein-induced neurotoxicity. Here we show that several small molecules, which delay aggregation of α-synuclein in solution, including the Parkinson’s disease drug selegiline, fail to interfere with misfolding of vesicle-bound α-synuclein. In contrast, the porphyrin phtalocyanine tetrasulfonate directly binds to vesicle-bound α-synuclein, stabilizes its helical conformation and thereby delays pathogenic misfolding and aggregation. Our study suggests that small-molecule-mediated stabilization of helical vesicle-bound α-synuclein opens new possibilities to target Parkinson’s disease and related synucleinopathies.

5 October 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AVAnna Villar-Piqué
Anna Villar-Piqué
TFTomás Lopes da Fonseca
Tomás Lopes da Fonseca
RSRicardo Sant’anna
Ricardo Sant’anna
ÉSÉva Mónika Szegö
Éva Mónika Szegö
LFLuis Fonseca-Ornelas
Luis Fonseca-Ornelas
Tiago OuteiroTiago Outeiro
Tiago Outeiro
Significance: Many neurodegenerative diseases are characterized by the abnormal accumulation of aggregated proteins in the brain. In Parkinson’s disease and related disorders, this process involves the accumulation of α-synuclein (aSyn). Thus, understanding the relationship between aSyn aggregation and pathological conditions is essential for the development of novel and efficient therapies against these disorders. Here, we studied the effects that different aSyn species have on neurons using a combination of neurodegeneration-associated factors: the H50Q aSyn mutant and the presence of copper. Importantly, we demonstrate that exogenous aSyn promotes toxicity and inclusion formation, and that these effects are inversely correlated. Our data shed light onto the pathological mechanisms associated with aSyn aggregation, forming the foundation for future therapeutic strategies.

1 July 2021 in Cell Reports
Verified
Journal Article
Open access
LFLuis Fonseca-Ornelas
Luis Fonseca-Ornelas
TVThibault Viennet
Thibault Viennet
MRMatteo Rovere
Matteo Rovere
HJHaiyang Jiang
Haiyang Jiang
LLLei Liu
Lei Liu
DSDennis J. Selkoe
Dennis J. Selkoe
While misfolding of alpha-synuclein (αSyn) is central to the pathogenesis of Parkinson's disease (PD), fundamental questions about its structure and function at the synapse remain unanswered. We examine synaptosomes from non-transgenic and transgenic mice expressing wild-type human αSyn, the E46K fPD-causing mutation, or an amplified form of E46K ("3K"). Synaptosomes from mice expressing the 3K mutant show reduced Ca2+-dependent vesicle exocytosis, altered synaptic vesicle ultrastructure, decreased SNARE complexes, and abnormal levels of certain synaptic proteins. With our intra-synaptosomal nuclear magnetic resonance (NMR) method, we reveal that WT αSyn participates in heterogeneous interactions with synaptic components dependent on endogenous αSyn and synaptosomal integrity. The 3K mutation markedly alters these interactions. The synaptic microenvironment is necessary for αSyn to reach its native conformations and establish a physiological interaction network. Its inability to populate diverse conformational ensembles likely represents an early step in αSyn dysfunction that contributes to the synaptotoxicity observed in synucleinopathies.